BRAF Antikörper

Produktnummer ABIN968991

Produktdetails anti-BRAF Antikörper

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reaktivität: Human, Maus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser BRAF Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Aufreinigung: purified

Immunogen: Purified recombinant fragment of human BRAF expressed in E. coli.

Klon: 1H12

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000, ICC: 1:200 - 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: 4°C, -20°C for long term storage

Referenzen für anti-BRAF Antikörper (ABIN968991)

Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, Issue 35, pp. 5705-12, (2008) (PubMed).

Riesco-Eizaguirre, Gutiérrez-Martínez, García-Cabezas, Nistal, Santisteban: "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane." in: Endocrine-related cancer, Vol. 13, Issue 1, pp. 257-69, (2006) (PubMed).

Details zu BRAF

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Andere Bezeichnung: BRAF (BRAF Produkte)

Synonyme: B-RAF1 antikoerper, BRAF1 antikoerper, NS7 antikoerper, RAFB1 antikoerper, C-RMIL antikoerper, RMIL antikoerper, B-Raf antikoerper, braf1 antikoerper, rafb1 antikoerper, b-raf1 antikoerper, sierrabraf antikoerper, BRAF antikoerper, 9930012E13Rik antikoerper, AA120551 antikoerper, AA387315 antikoerper, AA473386 antikoerper, B-raf antikoerper, Braf-2 antikoerper, Braf2 antikoerper, C230098H17 antikoerper, C87398 antikoerper, D6Ertd631e antikoerper, braf antikoerper, fc48g01 antikoerper, wu:fc48g01 antikoerper, B-Raf proto-oncogene, serine/threonine kinase antikoerper, B-Raf proto-oncogene, serine/threonine kinase S homeolog antikoerper, Braf transforming gene antikoerper, si:dkey-222f8.3 antikoerper, BRAF antikoerper, Braf antikoerper, braf.S antikoerper, braf antikoerper, si:dkey-222f8.3 antikoerper

Hintergrund:

Description: BRAF: v-raf murine sarcoma viral oncogene homolog B1, also known as BRAF1, RAFB1, B-RAF1, FLJ95109. Entrez Protein NP_004324. It is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439). B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK), it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi, primary cutaneous melanomas and colorectal cancers.

Aliases: BRAF1, RAFB1, B-RAF1, FLJ95109

Molekulargewicht: 87 kDa

Gen-ID: 673

HGNC: 673

Pathways: MAPK Signalweg, RTK Signalweg, Neurotrophin Signalübertragung, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagie